Please assess the completion status of the following clinical trial:

Trial Title: N-acetylcysteine in the Treatment of PTSD and Addiction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 year old~* U.S. military Veteran, Reservist, or National Guard member~* DSM-IV diagnostic criteria for current (past 6 months) SUD and PTSD or subthreshold PTSD (i.e., met criteria for cluster B (re-experiencing) and either cluster C (avoidance) or D (hyperarousal), as well as duration of one month and clinically significant impairment)~* Score of \> 21 on the Mini-Mental State Exam (MMSE).~Exclusion Criteria:~* Unstable medical conditions~* Bipolar or psychotic disorders~* Seizures or asthma~* Prior treatment with NAC~* Suicidality~* Enrolled in ongoing PTSD treatment (pharmacotherapy or psychosocial)~* Females: could not be pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- N-Acetylcysteine (Type: EXPERIMENTAL): Eligible participants were randomized to either NAC (2400 mg/day) or placebo for 8 weeks. The starting dose of NAC was 1200 mg twice daily (2400 mg/day). All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance.
- Placebo (Type: PLACEBO_COMPARATOR): Identical appearing placebo capsules were dispensed. All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance. Study medications (USP-grade NAC and matched placebo capsules) dispensed to participants by the medical clinician or study staff. Treatment assignment followed a pre-arranged randomization scheme and was carried out by study personnel at the pharmacy (i.e., personnel not involved in clinical management of participants to preserve the double-blind design).

Based on this trial design, predict the completion outcome and termination type (if applicable).